Targeted attack on Tough-to-Treat blood cancer
NCT ID NCT05600686
Summary
This study is testing a new two-step treatment for people with a high-risk, aggressive type of lymphoma who haven't had treatment yet. First, patients receive a targeted drug that seeks out and kills cancer cells, followed by a standard chemotherapy regimen. The goal is to see if this combination is more effective at controlling the cancer than current standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE-EXPRESSOR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UC San Diego Moores Cancer Center
RECRUITINGSan Diego, California, 92037, United States
Contact Email: •••••@•••••
Contact
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.